GlassScriptPhysician profile
Guillermo A Reyes
NPI 1164544656
$15,814.97
in general payments reported to CMS, 2019-2025
47 companies · $958 in 2025
The $958 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,420 · 2020: $2,765 · 2021: $2,720 · 2022: $2,088 · 2023: $1,729 · 2024: $3,135 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,821.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $3,201.50 | 2019-2025 | Renamic Neo, Biomonitor, Amvia Edge |
| Janssen Pharmaceuticals, INC | $2,397.90 | 2019-2024 | Xarelto |
| Bard Peripheral Vascular, INC. | $2,106.05 | 2019-2021 | |
| Scpharmaceuticals INC. | $977.28 | 2023-2025 | |
| Abbott Laboratories | $823.98 | 2020-2023 | Pressurewire, Hi-Torque Floppy, Mini Trek |
| Sanofi-Aventis U.S. LLC | $661.46 | 2019-2024 | |
| Cardiva Medical, INC. | $522.60 | 2024-2025 | Cardiva Vascade 6/7f Vcs, Optowire, Cardiva Vascade Mvp Vvcs 6-12f |
| Boehringer Ingelheim Pharmaceuticals, INC. | $479.14 | 2020-2025 | Jardiance |
| Pfizer INC. | $471.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $433.41 | 2019-2025 | Farxiga, Brilinta |
| Esperion Therapeutics, INC. | $396.91 | 2022-2025 | Nexletol |
| Philips North America LLC | $363.73 | 2020-2023 | |
| Impulse Dynamics (USA) INC. | $359.78 | 2022-2024 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $313.42 | 2019-2024 | Lifevest |
| Cardiovascular Systems INC. | $247.97 | 2020-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.